Investors

Explore how Hikma’s diversified portfolio, operational excellence, and global reach delivers value for investors

Hikma released its financial results for the year ended 31 December 2025 on Thursday 26 February 2026.
Latest news

Newsroom

All news stories

Hikma launches Diazepam Injection, USP in the US

Press Release, Product
New

Hikma launches XCOPRI® (Cenobamate tablets) in the UAE

Press Release, Product

Hikma welcomes FDA approval of Guardant360® Liquid CDx

Press Release, Product
New

Behind Better Health: Hikma's People

Insight, Life at Hikma

Hikma comments on Supreme Court of the United States’ unanimous decision in favour of Hikma

Press Release, Corporate

Hikma Pharmaceuticals puts access to medicines at the heart of its sustainability strategy, reaching 222 million patient...

Press Release, Corporate

Hikma launches Tofacitinib oral solution in the US

Press Release, Product
New

Inspired at Hikma: Career growth, leadership and social impact. Meet Zeena Murad

Story, Life at Hikma
New

Working at Hikma’s Zagreb R&D hub: meet Nera Marjanovic

Story, Life at Hikma
New

Why the world needs more companies like Hikma. By Said Darwazah, Chief Executive Officer

Insight, Corporate
Sign up here if you would like to receive email alerts with our latest results, regulatory news, and business updates.
Stay informed